Entrada Therapeutics, Inc.

Entrada Therapeutics is a company in Boston, United States, whose mission is to treat devastating diseases with intracellular therapeutics. Its proprietary Endosomal Escape Vehicle (EEV™) Platform is described as highly versatile and modular, designed to enable efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. The company is developing potential treatments spanning discovery to clinical-stage across retinal, neuromuscular and metabolic diseases, including Duchenne muscular dystrophy. Dipal Doshi serves as Chief Executive Officer.

Entrada Therapeutics is a company in Boston, United States. It states that it is driven to transform the lives of patients by establishing a new class of intracellular therapeutics, and that its mission is to treat devastating diseases with intracellular therapeutics. Its proprietary Endosomal Escape Vehicle (EEV™) Platform is described as highly versatile and modular, designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. The company is developing potential treatments spanning discovery to clinical-stage across retinal, neuromuscular and metabolic diseases, including Duchenne muscular dystrophy. In 2023 Entrada launched DREAMS, a competitive annual grant program that funds non-profit organizations' efforts to advance equity, inclusion and accessibility within the Duchenne muscular dystrophy community.

Driven to transform the lives of patients by establishing a new class of intracellular therapeutics.

1. 1Entrada Therapeutics | Making Intracellular Therapeutics A Realityentradatx.com
2. 2Entrada Therapeutics | Who We Areentradatx.com
3. 3Entrada Therapeutics | DREAMS Grant Programentradatx.com
4. 4Entrada Therapeutics | Careers at Entradaentradatx.com